Skip to main content

Clinical Trials Using Ipilimumab

Review the clinical trials studying ipilimumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-50 of 78

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Status: Active
Location: 4 locations
Neoadjuvant Immunotherapy in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
Status: Active
Location: 3 locations
Tazemetostat, Nivolumab, and Ipilimumab for the Treatment of SMARCB1- or SMARCA4-Deficient Tumors in Children, TAZNI Study
Status: Active
Location: 4 locations
Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitor for the Treatment of Triple Negative Breast Cancer
Status: Active
Location: 4 locations
Ipilimumab and Nivolumab with or without Hypofractionated Radiation Therapy in Treating Patients with Metastatic Melanoma
Status: Active
Location: 3 locations
Nivolumab, Relatlimab and Ipilimumab versus Nivolumab and Ipilimumab for the Treatment of Untreated Stage IV Renal Cell Cancer
Status: Active
Location: 3 locations
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Status: Active
Location: 4 locations
Immune Checkpoint Inhibition in Combination with Cryoablation for the Treatment of Patients Undergoing Surgery for Early Stage Triple-Negative Breast Cancer
Status: Active
Location: 2 locations
Nivolumab in Combination with Axitinib for the Treatment of Advanced or Unresectable Mucosal Melanoma
Status: Active
Location: 2 locations
Cabozantinib, Ipilimumab, Nivolumab, and Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma
Status: Active
Location: 2 locations
A Vaccine (VSV-IFNβ-NIS) in Combination with Cemiplimab and Ipilimumab for the Treatment of Recurrent Peripheral T-cell Lymphoma
Status: Active
Location: 2 locations
A Vaccine (VSV-hIFNβ-NIS) with or without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Status: Active
Location: 2 locations
A Microdevice for Candidate Drug Screening in Patients with Skin Squamous Cell Carcinoma
Status: Active
Location: 2 locations
High-Dose Interleukin-2, Ipilimumab and Nivolumab for the Treatment of Patients with Stage III-IV Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Axitinib and Ipilimumab for the Treatment of Advanced Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Time-of-Day Specified Ipilimumab and Nivolumab for the Treatment of Stage IV Unresectable Melanoma, The TIME Trial
Status: Active
Location: 2 locations
Immunotherapy and Cryoablation of an Enlarging Tumor for the Treatment of Unresectable Metastatic Melanoma
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Ipilimumab and Nivolumab before Surgery for the Treatment of Recurrent, High Risk, Resectable Stage IIIB-IV Metastatic Melanoma (NeoRelapse)
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Immunotherapy versus Chemoimmunotherapy Guided by Circulating Tumor DNA-Based Molecular Response for the Treatment of Stage IV Non-small Cell Lung Cancer
Status: Active
Location: 2 locations
Relatlimab, Nivolumab, and Ipilimumab for the Treatment of Unresectable or Metastatic Melanoma with Asymptomatic or Symptomatic Brain Metastases
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Combined Immunotherapy with Ipilimumab and Nivolumab or Nivolumab and Relatlimab and Radiation Therapy before Surgery for the Treatment of Sinonasal and Anorectal Melanoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Nivolumab, Ipilimumab, and Cabozantinib for the Treatment of Untreated Renal Cell Carcinoma with Brain Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Nivolumab Alone or in Combination with Relatlimab or Ipilimumab for the Treatment of Resectable Stage III-IVA Head and Neck Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Nivolumab with or without Ipilimumab or Relatlimab in Treating Patients with Unresectable, Metastatic, or Refractory Basal Cell Carcinoma
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Niraparib and Ipilimumab for the Treatment of Patients with Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on Platinum-Based Therapy, ParpVax2 Trial
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania